Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bromodomain-containing protein 8 (BRD8) is an epigenetic reader protein and a key component of the NuA4/TIP60 histone acetyltransferase complex (UniProt Q9H0E9; Yamaguchi et al., 2024). It contains two bromodomains, with Bromodomain 1 (BD1) being a critical module for recognizing acetylated lysine residues on histones H4 and H2AZ, as well as non-histone proteins like TWIST1 (Yamaguchi et al., 2024; PMID: 36544021). BRD8 functions as a transcriptional coactivator for several nuclear receptors, including the thyroid hormone receptor and androgen receptor, and plays a significant role in chromatin remodeling and DNA repair (UniProt Q9H0E9; GeneCards). In various cancers, such as glioblastoma and colorectal cancer, BRD8 is often overexpressed and acts as an oncogenic driver by maintaining a repressive chromatin state that sequesters the tumor suppressor p53, thereby preventing the activation of its target genes like p21 (PMID: 36544021; PMID: 38401187). Targeting the BD1 domain with small-molecule inhibitors, such as the chemical probe DN02, has been shown to displace H2AZ, restore p53-mediated growth arrest, and inhibit tumor progression (ProbeChem; PMID: 36544021). Consequently, BRD8 BD1 is an emerging therapeutic target for the treatment of TP53-wild-type malignancies and other epigenetic-driven diseases (PMID: 36544021).
Inhibition of the bromodomain 1 (BD1) module to disrupt the recognition of acetylated lysine residues on histones (H4, H2AZ) and non-histone proteins (TWIST1), thereby inducing chromatin remodeling and restoring tumor suppressor pathways such as p53-mediated transactivation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bromodomain-containing protein 8 (BRD8) Bromodomain 1 (BRD8 BD1).